Akthelia Pharmaceuticals

Akthelia Pharma is a late preclinical-stage immunotherapy company, with its HQ in Iceland, targeting a huge unmet opportunity to improve cancer and cell/organ transplant outcomes through reducing the risk of neutropenic sepsis. This potentially fatal complication of systemic anticancer treatment, where a combination of reduced neutrophil count and loss of GI integrity results in bacteremia from the patient's own microbiome, is the leading cause of death associated with chemotherapy (up to 20% mortality)- other than disease progression. Our breakthrough patented strategy, which is supported by world-leading KOLs, is to specifically upregulate the innate immunology and integrity of the GI tract wall, with exciting results indicating that we effectively block bacterial translocation, the principal underlying causal pathophysiology.